نتائج البحث - "Paul Lorigan"

1

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma

المساهمون: Medical Oncology, Clinical sciences, Laboratory of Molecular and Medical Oncology, Laboratory of Molecullar and Cellular Therapy

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Ipilimumab, Pembrolizumab, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Long term survival, medicine, In patient, business, 030215 immunology, medicine.drug, Advanced melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b58ea7696aac607a6b8b94623bd747Test
https://biblio.vub.ac.be/vubir/longterm-survival-from-pembrolizumab-pembro-completion-and-pembro-retreatment-phase-iii-keynote006-in-advanced-melanomaTest(06384d96-ea38-49d1-a40c-297993de00d7).html

2

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

المساهمون: University of Zurich, Nathan, Paul

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Medizin, Phases of clinical research, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Aged, 80 and over, Mucosal, Incidence (epidemiology), Mucosal melanoma, 10177 Dermatology Clinic, Middle Aged, Advanced melanoma, Acral, Ipilimumab, Nivolumab, Ocular, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, Diarrhea, medicine.medical_specialty, Adolescent, Ocular Melanoma, 610 Medicine & health, Skin Diseases, Drug Administration Schedule, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, neoplasms, Aged, business.industry, medicine.disease, 030104 developmental biology, Cutaneous melanoma, business

وصف الملف: 808_Nathan_P._et_al._Safety_and_efficacy_of_nivolumab_in_patients_with_rare_melanoma_subtypes_who_progressed_on_or_after_ipilimumab_treamtent_EJC_2019.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50fea214c572dced501f2350795c8ee0Test
https://www.zora.uzh.ch/id/eprint/174048Test/

3

Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small cell lung cancer

المؤلفون: Paul Lorigan, Samuel Rack, Cong Zhou, Nadina Tinsley, Natalie Cook, Fiona H Blackhall, Grace Chin Lay Tan, Sharon Nahm

المصدر: Journal of Clinical Oncology. 39:3100-3100

مصطلحات موضوعية: Cancer Research, business.industry, medicine.drug_class, Antibiotics, Cancer, computer.file_format, medicine.disease, Oncology, Cancer research, Medicine, In patient, ABX test, Antibiotic use, business, Lung cancer, computer, Tyrosine kinase, Advanced melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b58e5d2e2a682582a551b0658b90d3d2Test
https://doi.org/10.1200/jco.2021.39.15_suppl.3100Test

4

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)

المساهمون: University of Zurich, Schadendorf, Dirk

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, Medizin, Phases of clinical research, ECOG Performance Status, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Aged, 80 and over, Incidence (epidemiology), Advanced melanoma, Autoimmune, CNS metastasis, ECOG performance status, Ipilimumab, Nivolumab, 10177 Dermatology Clinic, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.symptom, medicine.drug, Adult, medicine.medical_specialty, 610 Medicine & health, Asymptomatic, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Adverse effect, Aged, Neoplasm Staging, business.industry, Survival Analysis, Clinical trial, 030104 developmental biology, Drug Resistance, Neoplasm, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48abb2e73d26f6fad8dfcfa853ddfd01Test
http://hdl.handle.net/11365/1083701Test

5

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006

المصدر: Long, G V, Schachter, J, Ribas, A, Arance, A M, Grob, J-J, Mortier, L, Daud, A, Carlino, M S, McNeil, C M, Lotem, M, Larkin, J M G, Lorigan, P, Neyns, B, Blank, C U, Petrella, T M, Hamid, O, Anderson, J, Krepler, C, Ibrahim, N & Robert, C 2018, ' 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ', pp. 9503-9503 . https://doi.org/10.1200/jco.2018.36.15_suppl.9503Test

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Ipilimumab, Pembrolizumab, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, business, medicine.drug, Advanced melanoma

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc84db92eee286fb74188833bd88a254Test
https://doi.org/10.1200/jco.2018.36.15_suppl.9503Test

6

The role of nivolumab in melanoma

المؤلفون: Paul Lorigan, Fabio Gomes, Patricio Serra-Bellver

المصدر: Future oncology (London, England). 14(13)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::538da8f3c45f444b3cd7cd3c6f3d6645Test
https://pubmed.ncbi.nlm.nih.gov/29328782Test

7

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

المؤلفون: C. Robert, Bart Neyns, S. Ebbinghaus, Jacob Schachter, Ana Arance, Mark R. Middleton, Georgina V. Long, Laurent Mortier, C. Blank, Honghong Zhou, A. Ribas, Mario Sznol, Neil Steven, Nuhad K. Ibrahim, Paul Lorigan

المساهمون: Faculty of Arts and Philosophy, Clinical sciences, Medical Oncology, Laboratory of Molecular and Medical Oncology, Laboratory of Molecullar and Cellular Therapy

مصطلحات موضوعية: Antitumor activity, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Ipilimumab, Pembrolizumab, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, business, medicine.drug, Advanced melanoma